MeiraGTx Holdings plc (MGTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USG596651020
MeiraGTx Holdings plc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 81.39 m USD |
| Operating income | -105.97 m USD |
| EBIT | -103.82 m USD |
| Net income | -114.20 m USD |
| Diluted EPS – continuing operations | -1.42 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
More stocks
- SUFA Technology Industry Co Ltd CNNC (000777.SZ)
- Alliance Material Co., Ltd. (3595.TWO)
- Fujian Apex Software Co Ltd (603383.SS)
- Samhyun (437730.KQ)
- Docebo Inc (DCBO.TO)
- LEGALZOOM.COM, INC. (LZ)
- China Resources Building Materials Technology Holdings Ltd (1313.HK)
- Zhuhai Comleader Information Science & Technology Co. Ltd. A (688175.SS)
- GRK Infra Oyj (GRK.HE)
- Seegene Inc (096530.KQ)
- Shenzhen Farben Information Technology Co.Ltd. (300925.SZ)
- ShuYu Civilian Pharmacy Corp. Ltd. (301017.SZ)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.